Clinuvel Pharmaceuticals Limited
17
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
29%
5 trials in Phase 3/4
69%
11 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
Role: lead
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
Role: lead
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Role: lead
Afamelanotide in Patients Suffering With Acne Vulgaris
Role: lead
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Role: lead
Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium
Role: lead
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
Role: lead
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Role: lead
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Role: lead
Multicentre Phase III Erythropoietic Protoporphyria Study
Role: lead
Phase III Confirmatory Study in Erythropoietic Protoporphyria
Role: lead
Implant Pharmacokinetic and Pharmacodynamic Study
Role: lead
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
Role: lead
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
Role: lead
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
Role: lead
Phase II AK Study in Organ Transplant Patients
Role: lead
Phase II Solar Urticaria (SU) Pilot Study
Role: lead
All 17 trials loaded